{
    "clinical_study": {
        "@rank": "94247", 
        "arm_group": {
            "arm_group_label": "17.5 mg of sodium risedronate", 
            "description": "17.5 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once daily after waking for 8 consecutive weeks."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of sodium risedronate\n      tablets (Benet 17.5 mg Tablets) administered once daily (one tablet per dose) in patients\n      with osseous Paget's disease for 48 weeks from baseline in daily medical practice."
        }, 
        "brief_title": "Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance \u2212", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Osseous Paget's Disease", 
        "condition_browse": {
            "mesh_term": "Osteitis Deformans"
        }, 
        "detailed_description": {
            "textblock": "This special drug use surveillance was designed to evaluate the safety and efficacy of\n      sodium risedronate tablets (Benet 17.5 mg Tablets) administered once daily (one tablet per\n      dose) in patients with osseous Paget's disease in daily medical practice.\n\n      The usual dosage for adults is 17.5 mg of sodium risedronate administered orally with a\n      sufficient volume (approximately 180 mL) of water once daily after waking for 8 consecutive\n      weeks. For at least 30 minutes after administration, patients should avoid lying in a supine\n      position and taking food, drink (except for water) or other oral drugs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Osseous Paget's disease patients treated with sodium risedronate tablets (Benet 17.5\n             mg Tablets)\n\n        Exclusion Criteria:"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Osseous Paget's disease"
            }
        }, 
        "enrollment": {
            "#text": "2500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106455", 
            "org_study_id": "067-211"
        }, 
        "intervention": {
            "arm_group_label": "17.5 mg of sodium risedronate", 
            "description": "Sodium risedronate tablets", 
            "intervention_name": "Sodium risedronate", 
            "intervention_type": "Drug", 
            "other_name": "Benet 17.5mg Tablets"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Risedronic acid", 
                "Etidronic Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Benet 17.5 mg Tablets Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) - 48-week Surveillance \u2212", 
        "overall_contact": {
            "email": "medicalinformation@tpna.com", 
            "last_name": "Takeda Study Registration Call Center", 
            "phone": "1-800-778-2860 (USA & EU)"
        }, 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The frequencies of all adverse events observed during the observation period will be tabulated by type and seriousness. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with administration of sodium risedronate whether or not it was considered related to treatment. Among these, events that are considered as having a causal relationship with sodium risedronate are defined as adverse drug reactions.", 
            "measure": "Frequency of adverse drug reactions", 
            "safety_issue": "Yes", 
            "time_frame": "For 48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106455"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percent change from Baseline in serum ALP will be tabulated.", 
                "measure": "Serum ALP", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Week 48"
            }, 
            {
                "description": "Percent changes from Baseline in bone metabolism markers will be tabulated.", 
                "measure": "Bone metabolism markers", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Week 48"
            }, 
            {
                "description": "Distribution of severity of pain associated with osseous Paget's disease will be tabulated.", 
                "measure": "Pain associated with osseous Paget's disease", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Week 48"
            }, 
            {
                "description": "Treatment compliance during the treatment period will be tabulated.", 
                "measure": "Treatment compliance", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Week 48"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2008", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}